VAXCYTE INC. - COMMON

Vaxcyte Appoints Whitney Jones as Chief People Officer

16 يناير 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

04 يناير 2024 15:01:42 بحسب Nasdaq GlobeNewswire

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

04 ديسمبر 2023 17:35:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Appoints Jacks Lee to Board of Directors

28 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

27 نوفمبر 2023 15:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

09 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

06 نوفمبر 2023 15:03:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

31 أكتوبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

19 أكتوبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

16 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

19 سبتمبر 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

08 أغسطس 2023 15:03:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

11 يوليو 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the Jefferies Healthcare Conference

01 يونيو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

08 مايو 2023 15:03:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

03 مايو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

21 أبريل 2023 16:25:10 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $500 Million Public Offering

18 أبريل 2023 23:26:49 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

17 أبريل 2023 15:05:14 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

17 أبريل 2023 05:30:00 بحسب Nasdaq GlobeNewswire